Table 2.
Cohort 2 Characteristics
| ID | Age, y | Sex | Years since diagnosis | Type of disease | Type of treatment before commencing anti-TNFα therapy | Harvey–Bradshaw Index |
||
|---|---|---|---|---|---|---|---|---|
| Week 0 | Week 8 | Week 24 | ||||||
| YVR001 | 28 | F | 12 | CD | Azathioprine, mesalamine | 10 | NA | 5 |
| YVR002 | 43 | F | 27 | CD | Budesonide | 7 | NA | NA |
| YVR003 | 55 | F | 7 | CD | None | NA | NA | NA |
| YVR004 | 55 | F | 25 | CD | Azathioprine | 0 | 1 | 1 |
| YVR005 | 27 | F | 2 | CD | Azathioprine, budesonide | 6 | 2 | 3 |
| YVR006 | 33 | M | 17 | CD | MTX | 1 | 5 | 3 |
| YVR007 | 22 | M | 7 | CD | None | 2 | 4 | 4 |
| YVR008 | 74 | F | 45 | CD | Prednisone | 2 | 6 | 1 |
| YVR009 | 60 | F | 20 | CD | Mesalamine | 5 | 1 | 2 |
| YVR010 | 54 | M | 19 | CD | Azathioprine | 9 | 5 | 0 |
| YVR011 | 35 | M | 7 | CD | MTX | 6 | 2 | 1 |
| YVR012 | 26 | M | 11 | CD | Azathioprine | 11 | 3 | 10 |
| YVR013 | 60 | F | 40 | CD | None | 3 | 0 | 0 |
| YVR014 | NA | NA | NA | CD | NA | 0 | 3 | 1 |
MTX, methotrexate; NA, data not available.